Pomerantz LLP files class action lawsuit against Skye Bioscience, Inc.

In a recent development, Pomerantz LLP has reported the initiation of a class action lawsuit against Skye Bioscience. The lawsuit alleges that Skye Bioscience violated federal securities laws. The law firm is currently seeking to represent any shareholders who suffered losses due to investing in Skye Bioscience between May 17, 2020, and November 16, 2025.

The lawsuit alleges that Skye Bioscience made false and misleading statements regarding the success of its product, SKYE-2A. The company claimed that SKYE-2A was on track to receive fast-track designation from the U.S. Food and Drug Administration (FDA) for the treatment of post-operative ocular inflammation. However, it is alleged that Skye Bioscience failed to disclose that SKYE-2A was not likely to receive FDA approval due to serious safety concerns.

It is further alleged that Skye Bioscience misrepresented the results of its clinical trials for SKYE-2A. The company claimed that the trials were successful and showed positive results. In reality, the lawsuit alleges that the trials were flawed and did not meet the necessary criteria to support the approval of SKYE-2A by the FDA.

As a result of these alleged misrepresentations, Skye Bioscience’s stock price was artificially inflated. When the true nature of SKYE-2A’s clinical trials and the likelihood of FDA approval were revealed, the stock price plummeted, causing significant losses to investors.

The lawsuit seeks to hold Skye Bioscience accountable for its alleged violations of federal securities laws and to recover damages on behalf of shareholders who suffered losses as a result of investing in the company. Shareholders who purchased Skye Bioscience stock between May 17, 2020, and November 16, 2025, are encouraged to contact Pomerantz LLP to participate in the class action lawsuit.

Investors are reminded that class action lawsuits provide an opportunity for shareholders who have suffered losses to seek justice and recover damages. By participating in a class action lawsuit, shareholders can hold companies accountable for their actions and seek compensation for any losses incurred as a result of securities fraud.

Pomerantz LLP is a respected law firm with a track record of successfully representing shareholders in class action lawsuits. The firm is dedicated to seeking justice for investors who have suffered losses due to securities fraud and other violations of federal securities laws.

If you are a shareholder who purchased Skye Bioscience stock between May 17, 2020, and November 16, 2025, and would like to learn more about participating in the class action lawsuit, please contact Pomerantz LLP for more information.